These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 11915937)
21. Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119). Beyer-Westendorf J; Marten S; Naue C; Tittl L; Sockel K; Middecke JM; Bornhäuser M Thromb Res; 2020 Jul; 191():50-55. PubMed ID: 32387685 [No Abstract] [Full Text] [Related]
22. Coagulation factor Xa: the prothrombinase complex as an emerging therapeutic target for small molecule inhibitors. Scarborough RM J Enzyme Inhib; 1998; 14(1):15-25. PubMed ID: 10520757 [No Abstract] [Full Text] [Related]
23. Oral and parenteral anticoagulants: new kids on the block. Aditya S J Postgrad Med; 2012; 58(4):275-85. PubMed ID: 23298923 [TBL] [Abstract][Full Text] [Related]
25. Fondaparinux sodium: a selective inhibitor of factor Xa. Bauer KA Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834 [TBL] [Abstract][Full Text] [Related]
26. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants? Papadaki S; Tselepis AD Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298 [TBL] [Abstract][Full Text] [Related]
27. Factor Xa inhibitors: critical considerations for clinical development and testing. Becker RC J Thromb Thrombolysis; 2021 Aug; 52(2):397-402. PubMed ID: 33991266 [TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban, an oral direct factor Xa inhibitor. Piccini JP; Patel MR; Mahaffey KW; Fox KA; Califf RM Expert Opin Investig Drugs; 2008 Jun; 17(6):925-37. PubMed ID: 18491993 [TBL] [Abstract][Full Text] [Related]
29. Mixing factor Xa and thrombin inhibiting direct oral anticoagulants produces a synergistic prolonging effect on most clotting tests. Exner T; Ellwood L; Dangol M; Favaloro EJ Int J Lab Hematol; 2023 Aug; 45(4):603-606. PubMed ID: 36808879 [No Abstract] [Full Text] [Related]
30. Newer anticoagulants in cardiovascular disease: a systematic review of the literature. Maan A; Padmanabhan R; Shaikh AY; Mansour M; Ruskin JN; Heist EK Cardiol Rev; 2012; 20(5):209-21. PubMed ID: 22370770 [TBL] [Abstract][Full Text] [Related]
31. Oral factor Xa and direct thrombin inhibitors: a clinical perspective. Thethi I; Lewis B; Fareed J J Burn Care Res; 2012; 33(4):453-61. PubMed ID: 22269826 [TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis. Fassiadis N Br J Hosp Med (Lond); 2011 Sep; 72(9):486. PubMed ID: 22041827 [No Abstract] [Full Text] [Related]
33. New advances in the discovery of thrombin and factor Xa inhibitors. Vacca JP Curr Opin Chem Biol; 2000 Aug; 4(4):394-400. PubMed ID: 10959766 [TBL] [Abstract][Full Text] [Related]
34. New oral anticoagulant drugs in cardiovascular disease. Ahrens I; Lip GY; Peter K Thromb Haemost; 2010 Jul; 104(1):49-60. PubMed ID: 20539909 [TBL] [Abstract][Full Text] [Related]
35. [Preclinical and clinical data of the synthetic Xa inhibitor fondaparinux (Arixtra(®))]. Suzuki I; Ozeki Y Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):117-26. PubMed ID: 22451467 [No Abstract] [Full Text] [Related]
36. Novel paediatric anticoagulants: a review of the current literature. Chan VH; Monagle P; Massicotte P; Chan AK Blood Coagul Fibrinolysis; 2010 Mar; 21(2):144-51. PubMed ID: 20135753 [TBL] [Abstract][Full Text] [Related]
37. Dual inhibitors of the blood coagulation enzymes. Kranjc A; Kikelj D Curr Med Chem; 2004 Oct; 11(19):2535-47. PubMed ID: 15544461 [TBL] [Abstract][Full Text] [Related]
39. Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials. Lavalle C; V Mariani M; Fedele F Future Oncol; 2020 Nov; 16(32):2591-2594. PubMed ID: 32805155 [No Abstract] [Full Text] [Related]